ASXL1 and acute myeloid leukemia: Rothenberg-Thurley et al. have analyzed the mutational profiling of 126 AML patients in pre-treatment and remission samples; 40% of these patients retained ≥1 mutation at remission with a VAF ≥2%; mutation persistence was most frequent in DNMT3A (65% of patients with mutations at diagnosis), SRSF2 (64%), TET2 (55%), ASXL1 (46%), and IDH1/IDH2 (30%) and was associated with reduced survival [112].